α-Lipoic Acid, Diabetic Neuropathy, and Nathan’s Prophecy
Open Access
- 16 January 2012
- journal article
- editorial
- Published by SAGE Publications in Angiology
- Vol. 63 (2) , 81-83
Abstract
Both oral and intravenous administration of alpha-lipoic acid (ALA) has been investigated as add-on treatment for diabetic peripheral neuropathy. The recent Neurological Assessment of Thioctic Acid in Diabetic Neuropathy (NATHAN) 1 trial has shown that 4-year oral ALA administration is of some value in achieving a clinically meaningful improvement and a slight delay in the progression of neuropathic deficits among patients with mild/moderate diabetic peripheral neuropathy. Despite these promising results, important questions remain to be answered, mainly appropriate patient selection and optimal treatment duration. Moreover, a cost-benefit analysis would be useful.Keywords
This publication has 21 references indexed in Scilit:
- Effect of Prior Intensive Insulin Treatment During the Diabetes Control and Complications Trial (DCCT) on Peripheral Neuropathy in Type 1 Diabetes During the Epidemiology of Diabetes Interventions and Complications (EDIC) StudyDiabetes Care, 2010
- Residual microvascular risk in diabetes: unmet needs and future directionsNature Reviews Endocrinology, 2009
- Prevalence of Polyneuropathy in Pre-Diabetes and Diabetes Is Associated With Abdominal Obesity and MacroangiopathyDiabetes Care, 2008
- Factors That Impact Symptomatic Diabetic Peripheral Neuropathy in Placebo-Administered Patients From Two 1-Year Clinical TrialsDiabetes Care, 2007
- A 6-Month, Randomized, Double-Masked, Placebo-Controlled Study Evaluating the Effects of the Protein Kinase C-β Inhibitor Ruboxistaurin on Skin Microvascular Blood Flow and Other Measures of Diabetic Peripheral NeuropathyDiabetes Care, 2007
- Impact of Disease Characteristics on the Efficacy of Duloxetine in Diabetic Peripheral Neuropathic PainDiabetes Care, 2007
- Oral Treatment With α-Lipoic Acid Improves Symptomatic Diabetic PolyneuropathyDiabetes Care, 2006
- Long-Term Effects of Ranirestat (AS-3201) on Peripheral Nerve Function in Patients With Diabetic Sensorimotor PolyneuropathyDiabetes Care, 2006
- The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With α-Lipoic AcidDiabetes Care, 2003
- Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (α-lipoic acid): A two year multicenter randomized double-blind placebo-controlled trial (ALADIN II)Free Radical Research, 1999